[AF] WHO Pharmaceuticals Newsletter No. 6, 2006

[Martín Cañás]

Estimadas y estimados,

Está disponible el último número de WHO Pharmaceuticals Newsletter No. 6, 
2006, con el siguiente contenido:

Regulatory Matters
Adalimumab, etanercept, infliximab -- Previous HBV infection to be evaluated 
.. 1
Dextropropoxyphene-paracetamol combination products -- Risk of overdose;
updated prescribing inf 1
Dopamine agonists -- Increased libido, gambling: class
effects.. 1
Imatinib -- Prescribing information revised for cardiac effects.. 2
Oseltamivir -- Prescribing information updated with neuropsychiatric 
events.. 2
Rituximab -- Bowel obstruction and gastrointestinal perforation .. 2
Rotavirus vaccine -- For oral administration only .. 3
Safety of Medicines
Benzocaine (local anaesthetic) -- Risk of metahemoglobinaemia.. 4
Cholesterol lowering drugs -- Linked with psychiatric reactions.. 4
Ezetimebe -- Reports of depression.. 4
Ezetimebe -- Reports of muscular disorders..4
Meningococcal conjugate vaccine -- Update on reports of Guillain Barre 
syndrome.. 5
Methadone -- Use for pain control may result in death.. 5
Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) -- Review
completed; overall benefit-risk fav .. 5
Terbinafine -- Serious adverse effects including Stevens-Johnson syndrome.. 
5
Tramadol-warfarin -- Reports of interaction .. 6
Feature
Twenty-ninth Annual Meeting of Representatives of the National Centres
Participating in the WHO Programme for International Drug Monitoring - 
Recommendations from working group

la dirección es
http://www.who.int/entity/medicines/publications/newsletter/2006news6.pdf


Saludos,

Martín

Martín Cañás
GAPURMED (Grupo Argentino Para el Uso Racional del Medicamento)
macanas en netverk.com.ar